Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Low density lipoprotein increased? 14 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Low density lipoprotein increased have been filed in association with INFLIXIMAB (Renflexis). This represents 0.0% of all adverse event reports for INFLIXIMAB.

14
Reports of Low density lipoprotein increased with INFLIXIMAB
0.0%
of all INFLIXIMAB reports
1
Deaths
8
Hospitalizations

How Dangerous Is Low density lipoprotein increased From INFLIXIMAB?

Of the 14 reports, 1 (7.1%) resulted in death, 8 (57.1%) required hospitalization, and 4 (28.6%) were considered life-threatening.

Is Low density lipoprotein increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 14 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Low density lipoprotein increased?

EVOLOCUMAB (1,024) INCLISIRAN (423) ALIROCUMAB (336) ROSUVASTATIN (241) ATORVASTATIN (217) EZETIMIBE (217) LOMITAPIDE (164) TOFACITINIB (135) FINGOLIMOD (132) SOMATROPIN (93)

Which INFLIXIMAB Alternatives Have Lower Low density lipoprotein increased Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Low density lipoprotein increased Reports All Drugs Causing Low density lipoprotein increased INFLIXIMAB Demographics